Work

Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran

Year: 2024
Type: article
Abstract: Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in IranIntroduction: Various medications for the treatment of coronavirus disease 2019 (COVID-19) have been introduced in outpatient and inpatient wards.Three of the referees are Nirmatrelvir/ritonavir (Paxlovid), Molnupiravir and Fluvoxamine.The aim of this study was to investigate the cost-effectiveness of these drugs in treatment of patients with mild to moderate COVID-19 in Iran.Methods: The present study was an economic evaluation study with the aim of investigating the cost-effectiveness of drugs.A two-part decision analysis model of decision tree model and Markov model was used to investigate costeffectiveness.The study parameters included hospitalization, death rate, drugs, quality of life and treatment costs in 2022. Results:The results showed that standard treatment had higher cost and lower average outcome (QALY) compared to the average fluvoxamine.Molnopyravir had a higher average cost (202.205.422 vs. 155.243.881) and lower QALY (4.352 vs. 4.363).The average cost of Paxlovid was higher (133,712,604 Rials vs. 3,328,029) and the average QALY (0.969 vs. 0.966).The cost-effectiveness ratio of pexelloids compared with fluvoxamine was 302.781.040.50Rials.If the cost of the course of treatment with pexelloids is less than 2.108.425Rials, this drug will be cost-effective. Conclusion:It can be concluded that the use of paxlovid and molnopyravir in the treatment of COVID-19 patients in the mild to moderate stage who are at high risk for disease progression is not cost-effective at current prices.In the case of fluvoxamine, although the drug is cost-effective based on the available evidence, there is a lot of uncertainty about its effectiveness.
Language: Persian
Open Access status: hybrid
OpenAlex ID: W7166315341
FWCI:
Cites: 11
Cited by:
Related to: 9